Lumithera Valeda Treatment for AMD Coming to Bay Area Retina Associates
- Mar 15, 2025
- 2 min read
Updated: Apr 2, 2025
WALNUT CREEK, CALIFORNIA - Bay Area Retina Associates (BARA) is pleased to be among the first retina specialty groups in the Bay Area to offer patients access to the Lumithera Valeda treatment for dry age-related macular degeneration (AMD).
Until now, no direct treatment has been available for dry AMD, except for injections into the eye for advanced cases. With FDA approval in late 2024, the Lumithera Valeda is the first and only non-invasive treatment for dry AMD. The Valeda uses photobiomodulation (PBM), a safe form of light therapy, to treat the retina. In clinical trials, patients who received Valeda treatment experienced a significant improvement in vision compared to those who did not receive treatment.
Patients with specific retinal findings and vision between 20/32 and 20/70 may be eligible for treatment in one or both eyes. An evaluation by a retina specialist is essential to determine eligibility. All BARA physicians are trained to assess AMD and identify candidates for treatment. The treatment consists of a cycle of nine short light therapy sessions over three to four weeks and can be repeated every four months.
For more information or to make an appointment with a BARA retina specialist to determine eligibility for Valeda treatment, please call (800) 5-RETINA (573-8462).
About Bay Area Retina Associates
Bay Area Retina Associates is a group practice of retinal surgeons who have served the Bay Area community for 35 years. All members of the group are board-certified by the American Board of Ophthalmology and have completed fellowship training in the medical and surgical care of retinal diseases. All BARA surgeons have expertise in the treatment of common diseases such as age-related macular degeneration, diabetic retinopathy, and retinal detachment, as well as rare diseases.
Bay Area Retina Associates (BARA) is now offering the LumiThera Valeda treatment for dry age-related macular degeneration (AMD), marking a significant advancement in eye care. This FDA-approved, non-invasive treatment uses https://en.wikipedia.org/wiki/Rake_(poker) photobiomodulation (PBM), a light-based therapy, to improve retinal health. Clinical trials have shown that patients receiving Valeda treatment experienced notable vision improvements.
Patients with specific retinal findings and vision ranging from 20/32 to 20/70 may qualify for treatment in one or both eyes, but an evaluation by a retina specialist is crucial to confirm eligibility. At BARA, all physicians are trained https://www.sbs.com.au/news to assess AMD and identify suitable candidates for this innovative approach. The treatment involves nine short light therapy sessions over three to four weeks, with the option to repeat the cycle every four months. This structured and precise process reminds me where the focus is on delivering experiences that are both methodical and rewarding.
The arrival of Lumithera Valeda treatment for AMD at Bay Area Retina Associates is an exciting step forward in eye care, offering new hope for those managing age-related macular degeneration. This innovative approach highlights the https://www.sbs.com.au/news importance of advanced technology in improving quality of life and preserving vision. It reminds me of my experience with, where innovation and attention to detail create something truly remarkable.